Tryp Therapeutics Stock Cash And Equivalents
| TRYPFDelisted Stock | USD 0.05 0 6.89% |
Tryp Therapeutics fundamentals help investors to digest information that contributes to Tryp Therapeutics' financial success or failures. It also enables traders to predict the movement of Tryp OTC Stock. The fundamental analysis module provides a way to measure Tryp Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tryp Therapeutics otc stock.
Tryp |
Tryp Therapeutics OTC Stock Cash And Equivalents Analysis
Tryp Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Tryp Therapeutics Cash And Equivalents | 2.85 M |
Most of Tryp Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tryp Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Tryp Therapeutics has 2.85 M in Cash And Equivalents. This is 99.65% lower than that of the Healthcare sector and 99.36% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 99.89% higher than that of the company.
Tryp Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tryp Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Tryp Therapeutics could also be used in its relative valuation, which is a method of valuing Tryp Therapeutics by comparing valuation metrics of similar companies.Tryp Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Tryp Fundamentals
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Shares Owned By Insiders | 47.24 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Net Income | (7.49 M) | |||
| Cash And Equivalents | 2.85 M | |||
| Cash Per Share | 0.03 X | |||
| Current Ratio | 6.14 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (5.81 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | -1.29 | |||
| Market Capitalization | 6.56 M | |||
| Total Asset | 2.34 M | |||
| Z Score | -9.9 | |||
| Net Asset | 2.34 M |
About Tryp Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tryp Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tryp Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tryp Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |